NASDAQ:CTMX CytomX Therapeutics (CTMX) Stock Price, News & Analysis $0.84 -0.01 (-0.84%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About CytomX Therapeutics Stock (NASDAQ:CTMX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CytomX Therapeutics alerts:Sign Up Key Stats Today's Range$0.82▼$0.8650-Day Range$0.84▼$1.2952-Week Range$0.79▼$5.85Volume620,234 shsAverage Volume992,394 shsMarket Capitalization$65.74 millionP/E Ratio4.94Dividend YieldN/APrice Target$5.77Consensus RatingModerate Buy Company OverviewCytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Read More… CytomX Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks93rd Percentile Overall ScoreCTMX MarketRank™: CytomX Therapeutics scored higher than 93% of companies evaluated by MarketBeat, and ranked 77th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingCytomX Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageCytomX Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about CytomX Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CytomX Therapeutics are expected to decrease in the coming year, from ($0.05) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CytomX Therapeutics is 4.94, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 111.80.Price to Earnings Ratio vs. SectorThe P/E ratio of CytomX Therapeutics is 4.94, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.34.Read more about CytomX Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.13% of the outstanding shares of CytomX Therapeutics have been sold short.Short Interest Ratio / Days to CoverCytomX Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CytomX Therapeutics has recently decreased by 13.36%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytomX Therapeutics does not currently pay a dividend.Dividend GrowthCytomX Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.74 Percentage of Shares Shorted6.13% of the outstanding shares of CytomX Therapeutics have been sold short.Short Interest Ratio / Days to CoverCytomX Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CytomX Therapeutics has recently decreased by 13.36%, indicating that investor sentiment is improving significantly. News and Social Media3.3 / 5News Sentiment0.94 News SentimentCytomX Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for CytomX Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for CTMX on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat Follows6 people have added CytomX Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CytomX Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.00% of the stock of CytomX Therapeutics is held by insiders.Percentage Held by Institutions67.77% of the stock of CytomX Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about CytomX Therapeutics' insider trading history. Receive CTMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CTMX Stock News HeadlinesCytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJanuary 19 at 3:39 AM | americanbankingnews.comBay Area biotech firm CytomX, once worth $2.3 billion, lays off 40% of staffJanuary 15, 2025 | msn.comGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of a lifetime! January 20, 2025 | Crypto 101 Media (Ad)CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | markets.businessinsider.comPiper Sandler Sticks to Its Buy Rating for CytomX Therapeutics (CTMX)January 8, 2025 | markets.businessinsider.comCytomX Therapeutics Inc.: CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate UpdateJanuary 7, 2025 | finanznachrichten.deCytomX Therapeutics (CTMX) Gets a Buy from BarclaysJanuary 7, 2025 | markets.businessinsider.comCytomX Therapeutics (CTMX) Receives a Buy from WedbushJanuary 7, 2025 | markets.businessinsider.comSee More Headlines CTMX Stock Analysis - Frequently Asked Questions How have CTMX shares performed this year? CytomX Therapeutics' stock was trading at $1.03 at the start of the year. Since then, CTMX shares have decreased by 18.4% and is now trading at $0.84. View the best growth stocks for 2025 here. How were CytomX Therapeutics' earnings last quarter? CytomX Therapeutics, Inc. (NASDAQ:CTMX) posted its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.23. The biotechnology company had revenue of $33.43 million for the quarter, compared to analyst estimates of $18.92 million. CytomX Therapeutics had a net margin of 10.96% and a negative trailing twelve-month return on equity of 41.47%. Who are CytomX Therapeutics' major shareholders? CytomX Therapeutics' top institutional investors include Congress Park Capital LLC (1.23%), Assenagon Asset Management S.A. (0.77%) and Traphagen Investment Advisors LLC (0.04%). Insiders that own company stock include Sean A Mccarthy, Marcia Belvin, Jeffrey B Landau, Lloyd A Rowland, Christopher Ogden, Amy C Peterson, Carlos Campoy and Elaine V Jones. View institutional ownership trends. How do I buy shares of CytomX Therapeutics? Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CytomX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CytomX Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), CymaBay Therapeutics (CBAY), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings11/07/2024Today1/20/2025Next Earnings (Estimated)3/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CTMX CUSIPN/A CIK1501989 Webwww.cytomx.com Phone(605) 515-3185Fax650-351-0353Employees170Year FoundedN/APrice Target and Rating Average Stock Price Target$5.77 High Stock Price Target$8.00 Low Stock Price Target$3.50 Potential Upside/Downside+587.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$0.17 Trailing P/E Ratio4.94 Forward P/E RatioN/A P/E GrowthN/ANet Income$-570,000.00 Net Margins10.96% Pretax Margin11.89% Return on Equity-41.47% Return on Assets8.11% Debt Debt-to-Equity RatioN/A Current Ratio1.04 Quick Ratio1.04 Sales & Book Value Annual Sales$101.21 million Price / Sales0.65 Cash FlowN/A Price / Cash FlowN/A Book Value($0.71) per share Price / Book-1.18Miscellaneous Outstanding Shares78,260,000Free Float72,781,000Market Cap$65.74 million OptionableOptionable Beta1.03 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report This page (NASDAQ:CTMX) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.